Prevention of Preeclampsia and Eclampsia

Baha M. Sibai, F. Gary Cunningham

Research output: Chapter in Book/Report/Conference proceedingChapter

14 Citations (Scopus)

Abstract

The precise pathogenesis of convulsions with the preeclampsia syndrome is enigmatic, the two prevailing schemes are vasospasm with ischemia and hypertensive encephalopathy. Eclampsia prevention can be primary by preventing worsening of preeclampsia; it can be secondary by using agents to prevent convulsions in women with established preeclampsia; and it can be tertiary by preventing recurrent convulsions in women with eclampsia. The decision to use secondary prophylaxis would in some regards depend on the likelihood of eclamptic convulsions in women with preeclampsia. Thus the use Magnesium Sulfate is used in mild and severe preeclampsia. The primary objective of magnesium sulfate prophylaxis in women with preeclampsia is to prevent or reduce the rate of eclampsia and associated complications. Other benefits include reduced maternal and perinatal mortalities and morbidities. In addition, in women with mild preeclampsia, a secondary benefit might include a decreased rate of progression to severe preeclampsia.

Original languageEnglish (US)
Title of host publicationChesley's Hypertensive Disorders in Pregnancy
PublisherElsevier Inc.
Pages213-225
Number of pages13
ISBN (Print)9780123742131
DOIs
StatePublished - Dec 1 2009

Fingerprint

Eclampsia
Pre-Eclampsia
Seizures
Magnesium Sulfate
Hypertensive Encephalopathy
Maternal Mortality
Perinatal Mortality
Ischemia
Morbidity

ASJC Scopus subject areas

  • Dentistry(all)
  • Medicine(all)

Cite this

Sibai, B. M., & Gary Cunningham, F. (2009). Prevention of Preeclampsia and Eclampsia. In Chesley's Hypertensive Disorders in Pregnancy (pp. 213-225). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-374213-1.00012-4

Prevention of Preeclampsia and Eclampsia. / Sibai, Baha M.; Gary Cunningham, F.

Chesley's Hypertensive Disorders in Pregnancy. Elsevier Inc., 2009. p. 213-225.

Research output: Chapter in Book/Report/Conference proceedingChapter

Sibai, BM & Gary Cunningham, F 2009, Prevention of Preeclampsia and Eclampsia. in Chesley's Hypertensive Disorders in Pregnancy. Elsevier Inc., pp. 213-225. https://doi.org/10.1016/B978-0-12-374213-1.00012-4
Sibai BM, Gary Cunningham F. Prevention of Preeclampsia and Eclampsia. In Chesley's Hypertensive Disorders in Pregnancy. Elsevier Inc. 2009. p. 213-225 https://doi.org/10.1016/B978-0-12-374213-1.00012-4
Sibai, Baha M. ; Gary Cunningham, F. / Prevention of Preeclampsia and Eclampsia. Chesley's Hypertensive Disorders in Pregnancy. Elsevier Inc., 2009. pp. 213-225
@inbook{7adb80b6228c46ec9013d91029d3fa67,
title = "Prevention of Preeclampsia and Eclampsia",
abstract = "The precise pathogenesis of convulsions with the preeclampsia syndrome is enigmatic, the two prevailing schemes are vasospasm with ischemia and hypertensive encephalopathy. Eclampsia prevention can be primary by preventing worsening of preeclampsia; it can be secondary by using agents to prevent convulsions in women with established preeclampsia; and it can be tertiary by preventing recurrent convulsions in women with eclampsia. The decision to use secondary prophylaxis would in some regards depend on the likelihood of eclamptic convulsions in women with preeclampsia. Thus the use Magnesium Sulfate is used in mild and severe preeclampsia. The primary objective of magnesium sulfate prophylaxis in women with preeclampsia is to prevent or reduce the rate of eclampsia and associated complications. Other benefits include reduced maternal and perinatal mortalities and morbidities. In addition, in women with mild preeclampsia, a secondary benefit might include a decreased rate of progression to severe preeclampsia.",
author = "Sibai, {Baha M.} and {Gary Cunningham}, F.",
year = "2009",
month = "12",
day = "1",
doi = "10.1016/B978-0-12-374213-1.00012-4",
language = "English (US)",
isbn = "9780123742131",
pages = "213--225",
booktitle = "Chesley's Hypertensive Disorders in Pregnancy",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Prevention of Preeclampsia and Eclampsia

AU - Sibai, Baha M.

AU - Gary Cunningham, F.

PY - 2009/12/1

Y1 - 2009/12/1

N2 - The precise pathogenesis of convulsions with the preeclampsia syndrome is enigmatic, the two prevailing schemes are vasospasm with ischemia and hypertensive encephalopathy. Eclampsia prevention can be primary by preventing worsening of preeclampsia; it can be secondary by using agents to prevent convulsions in women with established preeclampsia; and it can be tertiary by preventing recurrent convulsions in women with eclampsia. The decision to use secondary prophylaxis would in some regards depend on the likelihood of eclamptic convulsions in women with preeclampsia. Thus the use Magnesium Sulfate is used in mild and severe preeclampsia. The primary objective of magnesium sulfate prophylaxis in women with preeclampsia is to prevent or reduce the rate of eclampsia and associated complications. Other benefits include reduced maternal and perinatal mortalities and morbidities. In addition, in women with mild preeclampsia, a secondary benefit might include a decreased rate of progression to severe preeclampsia.

AB - The precise pathogenesis of convulsions with the preeclampsia syndrome is enigmatic, the two prevailing schemes are vasospasm with ischemia and hypertensive encephalopathy. Eclampsia prevention can be primary by preventing worsening of preeclampsia; it can be secondary by using agents to prevent convulsions in women with established preeclampsia; and it can be tertiary by preventing recurrent convulsions in women with eclampsia. The decision to use secondary prophylaxis would in some regards depend on the likelihood of eclamptic convulsions in women with preeclampsia. Thus the use Magnesium Sulfate is used in mild and severe preeclampsia. The primary objective of magnesium sulfate prophylaxis in women with preeclampsia is to prevent or reduce the rate of eclampsia and associated complications. Other benefits include reduced maternal and perinatal mortalities and morbidities. In addition, in women with mild preeclampsia, a secondary benefit might include a decreased rate of progression to severe preeclampsia.

UR - http://www.scopus.com/inward/record.url?scp=84882484750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882484750&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-374213-1.00012-4

DO - 10.1016/B978-0-12-374213-1.00012-4

M3 - Chapter

AN - SCOPUS:84882484750

SN - 9780123742131

SP - 213

EP - 225

BT - Chesley's Hypertensive Disorders in Pregnancy

PB - Elsevier Inc.

ER -